Navigating key news stories in pharma

IPEC 2026

Featured Stories

Featured
Weathering Headwinds: Bio/Pharma’s Roadmap for Success in 2026
Future Biopharma
Weathering Headwinds: Bio/Pharma’s Roadmap for Success in 2026
Future Biopharma

Despite geopolitical uncertainties, regulatory reforms, and fluctuating capital expenditure, the bio/pharma industry is entering 2026 with renewed focus and confidence.

Read More →
Future Biopharma
News
Partnership Set Up to Address Growing Demand for Self-Administered Therapies
Dealmaking
Partnership Set Up to Address Growing Demand for Self-Administered Therapies
Dealmaking

A manufacturing collaboration between ten23 health and BD will support the commercialization of a wearable injector platform that offers a ready-to-use option for subcutaneous administration of high-dose biologics.

Dealmaking
Systematic Review Shows No Evidence of Link Between Acetaminophen and Autism
Misc.
Systematic Review Shows No Evidence of Link Between Acetaminophen and Autism
Misc.

Claims that the use of acetaminophen/paracetamol while pregnant is linked to autism have been effectively disproved through a rigorous review and meta-analysis of current evidence.

Misc.
Vetter Advances Next-Generation Tamper-Evident Syringe Closure Towards Launch
R&D
Vetter Advances Next-Generation Tamper-Evident Syringe Closure Towards Launch
R&D

The company has advanced its next‑generation tamper‑evident syringe closure from design finalization to industrialization ahead of a planned 2027 launch to strengthen its position in prefilled drug‑delivery solutions.

R&D

R&D

Featured
Vetter Advances Next-Generation Tamper-Evident Syringe Closure Towards Launch
Vetter Advances Next-Generation Tamper-Evident Syringe Closure Towards Launch

The company has advanced its next‑generation tamper‑evident syringe closure from design finalization to industrialization ahead of a planned 2027 launch to strengthen its position in prefilled drug‑delivery solutions.

SGS Strengthens RSV Vaccine Research with Launch of Challenge Agent
SGS Strengthens RSV Vaccine Research with Launch of Challenge Agent

A new RSV A-strain challenge agent has been introduced by SGS to enhance CHIM studies and accelerate vaccine development. The breakthrough aims to generate more accurate, data-driven insights into RSV infection and immune response.

GSK, LTZ Therapeutics Collaborate on Next-Gen Immunotherapies
GSK, LTZ Therapeutics Collaborate on Next-Gen Immunotherapies

The companies will leverage GSK’s scientific expertise with LTZ’s immune engager platform to develop new first-in-class MCE therapies for the treatment of hematologic cancers and solid tumors.

Gene Therapy Improves Hearing in Children with Profound Genetic Hearing Loss
Gene Therapy Improves Hearing in Children with Profound Genetic Hearing Loss

Regeneron’s investigational gene therapy, DB-OTO, has been found to provide meaningful improvements in hearing for nearly all of the participants in the CHORD clinical trial.

Expansion

Featured
Novartis Invests in End-to-End Manufacturing in U.S.
Novartis Invests in End-to-End Manufacturing in U.S.

The company is creating a new flagship manufacturing hub in North Carolina that will enable end-to-end manufacturing of its key medicines in one geographic location.

Spinout Ensorcell Launches with Three Flagship Life Science Tools
Spinout Ensorcell Launches with Three Flagship Life Science Tools

Backed by the expert team and cutting-edge resources of Re:Build Manufacturing, Ensorcell will offer innovative, high-quality scientific tools designed to accelerate discoveries and improve patient outcomes.

Wilmington PharmaTech Secures Major Investment to Accelerate Expansion
Wilmington PharmaTech Secures Major Investment to Accelerate Expansion

A significant investment from Curewell Capital has been secured by Wilmington PharmaTech, providing growth capital to expand manufacturing and technology capabilities to accelerate drug development with U.S. manufacturing.

Lilly Grows European Manufacturing Capacity with New Facility in The Netherlands
Lilly Grows European Manufacturing Capacity with New Facility in The Netherlands

The USD 3 billion facility will expand the company’s capacity to produce oral medicines, enabling it to meet rising customer demand, and will also strengthen its global supply chain.

Dealmaking

Featured
Partnership Set Up to Address Growing Demand for Self-Administered Therapies
Partnership Set Up to Address Growing Demand for Self-Administered Therapies

A manufacturing collaboration between ten23 health and BD will support the commercialization of a wearable injector platform that offers a ready-to-use option for subcutaneous administration of high-dose biologics.

AbbVie, RemeGen Sign Exclusive Licensing Agreement for Novel Bispecific Antibody
AbbVie, RemeGen Sign Exclusive Licensing Agreement for Novel Bispecific Antibody

The agreement will allow AbbVie to develop, manufacture, and commercialize RemeGen’s novel PD-1/VEGF bispecific antibody in combination with its ADCs across multiple solid tumors.

Servier Taps Insilico's Pharma.AI in Multi-Billion Oncology Deal
Servier Taps Insilico's Pharma.AI in Multi-Billion Oncology Deal

Insilico Medicine has entered a multi‑year R&D collaboration with Servier to discover and develop novel AI‑designed oncology therapies. The deal will combine Insilico’s Pharma.AI platform with Servier’s global oncology development and commercialization capabilities.

Moderna Signs Licensing Deal with Nanexa to Explore Long-Acting Injectable Formulations
Moderna Signs Licensing Deal with Nanexa to Explore Long-Acting Injectable Formulations

Sweden’s Nanexa has entered a licensing and option deal with Moderna, granting access to its PharmaShell drug delivery platform to develop long-acting versions of Moderna’s mRNA-based therapies.

Strategy

Featured
Delivering Success — The Importance of Considering Drug Delivery Early
Delivering Success — The Importance of Considering Drug Delivery Early

As chronic diseases rise globally, the bio/pharma industry is pivoting toward increasingly complex molecules that demand more sophisticated delivery strategies, which must be considered early on in development.

Cellular Origins Completes Series A Financing Round
Cellular Origins Completes Series A Financing Round

The raised funds, totaling USD 40 million, will be used to accelerate the company’s growth and to advance its robotic platform, Constellation, which enables flexible, scalable cell therapy manufacturing.

Lilly Cuts Price of Tirzepatide Single-dose Vials to Increase Patient Affordability
Lilly Cuts Price of Tirzepatide Single-dose Vials to Increase Patient Affordability

As demand for GLP-1 obesity drugs surges and affordability remains a competitive factor in the global weight-loss market, Eli Lilly slashes tirzepatide vial prices to boost access for self-pay patients.

Meeting New Manufacturing Demands by Investing in Flexibility
Meeting New Manufacturing Demands by Investing in Flexibility

A fundamental, digitally driven overhaul of bio/pharmaceutical manufacturing models are needed to meet the demands of current global supply chain pressures and rising complexity of novel therapeutics.

Future Biopharma

Featured
Weathering Headwinds: Bio/Pharma’s Roadmap for Success in 2026
Weathering Headwinds: Bio/Pharma’s Roadmap for Success in 2026

Despite geopolitical uncertainties, regulatory reforms, and fluctuating capital expenditure, the bio/pharma industry is entering 2026 with renewed focus and confidence.

The Outsourcing Pivot for Bio/Pharma Innovation
The Outsourcing Pivot for Bio/Pharma Innovation

Facing a world of political risk and scientific hurdles, pharma companies are downsizing internal footprints to focus on portfolio management while leaning on CDMOs for specialized execution, explains Owen Murray from Bend Bioscience.

Pharmapack 2026: Moving Toward a Large-Volume Future
Pharmapack 2026: Moving Toward a Large-Volume Future

From managing high viscosity to preventing agglomeration, the industry is shifting toward larger-volume, device-compatible solutions that prioritize both drug stability and healthcare efficiency, points out Dr. Robert Lindner from SCHOTT Pharma.

Pharmapack 2026: A New Era of Accountable Pharma Packaging
Pharmapack 2026: A New Era of Accountable Pharma Packaging

Changes to sustainability reporting requirements are leading to renewed focus on supplier tools and packaging tenders, and driving a greater need for industry to adapt to ESG standards, reveals Morten Munk from FUJIFILM Biotechnologies.

Regulatory

Featured
Xenon Presents Clinical and Regulatory Milestones at J.P. Morgan Healthcare Conference
Xenon Presents Clinical and Regulatory Milestones at J.P. Morgan Healthcare Conference

The company is advancing its lead KV7 potassium channel modulator azetukalner through multiple Phase III trials in epilepsy and mood disorders, and planning its transition to commercial-stage growth.

AstraZeneca Gains Nod from FDA for Perioperative Imfinzi-Based Regimen
AstraZeneca Gains Nod from FDA for Perioperative Imfinzi-Based Regimen

The regulator’s decision will provide a new clinical option for patients with early gastric and gastroesophageal cancers that can deliver a significant survival benefit versus chemotherapy alone.

Circio Unveils Next-Generation Circular RNA Expression Platform
Circio Unveils Next-Generation Circular RNA Expression Platform

The company’s circVec 4.0 demonstrates unprecedented gene expression levels in heart and brain tissues to open new therapeutic opportunities across multiple organs.

Nanoform Secures European Commercial CGMP Manufacturing License
Nanoform Secures European Commercial CGMP Manufacturing License

Having secured a European Commercial CGMP Manufacturing License from FIMEA, Nanoform is now able to produce and control the quality of nanoformed APIs for Europe and other key markets.

Upcoming Events

Featured
DDR Inhibitors Summit 2026

Returning to Boston for its 9th year, the DDR Inhibitors Summit is the definitive meeting for senior decision-makers driving innovation in DNA Damage Response (DDR)-targeted oncology. With PARP inhibitors clinically validated for almost a decade, the field is now on the cusp of the next inhibitor class approval.

Ophthalmic Drug Delivery Summit 2026

The 4th Ophthalmic Drug Delivery Summit arrives at a pivotal moment, bringing together 80+ leading experts from pharma and biotech to tackle the toughest delivery hurdles limiting the impact of cutting-edge therapeutics.

WCBP 2026

The WCBP Scientific Organizing Committee, which includes individuals representing industry, academia, and regulatory agencies, is looking forward to welcoming everyone. From first-time attendees to those who have attended in previous years, WCBP 2026 will offer something for everyone.